Advertisement

Drug Safety

, Volume 29, Issue 10, pp 1068–1068 | Cite as

ABSTRACTS: ISoP Annual Conference ‘Joining Forces for Managing Risks’ Liège, Belgium 11–13 October, 2006

  • M. C. H. de Groot
  • E. P. van Puijenbroek
  • A. C. van Grootheest
Abstracts
  • 13 Downloads

Keywords

Lidocaine Halothane Fluconazole Ventricular Tachycardia Sevoflurane 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Dutch SPC Sevorane®. (version date 24-5-2005) http://www.cbg-meb.nl/IBteksten/18395.pdfGoogle Scholar
  2. 2.
    van Tuijl I, van Vught AJ. Kamertachycardie bij uitleiding uit anesthesie door medicamenteus geïnduceerd verlengd QT-interval. Tijdschr Kindergeneeskd 2003; 71(6): 246–8Google Scholar
  3. 3.
    Schmeling WT, Warltier DC, McDonald DJ, et al. Prolongation of the QT interval by enflurane, isoflurane, and halothane in humans. Anesth Analg 1991; 72(2): 137–44PubMedCrossRefGoogle Scholar
  4. 4.
    Abe K, Takada K, Yoshiya I. Intraoperative torsade de pointes ventricular tachycardia and ventricular fibrillation during sevoflurane anesthesia. Anesth Analg 1998; 86(4): 701–2PubMedGoogle Scholar
  5. 5.
    Kuenszberg E, Loeckinger A, Kleinsasser A, et al. Sevoflurane progressively prolongs the QT interval in unpremedicated female adults. Eur J Anaesthesiol 2000; 17(11): 662–4PubMedGoogle Scholar
  6. 6.
    Park WK, Pancrazio JJ, Suh CK, et al. Myocardial depressant effects of sevoflurane. Mechanical and electrophysiologic actions in vitro. Anesthesiology 1996; 84(5): 1166–76PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  • M. C. H. de Groot
    • 1
  • E. P. van Puijenbroek
    • 1
  • A. C. van Grootheest
    • 1
  1. 1.Netherlands Pharmacovigilance Centre Lareb’S-Hertogenboschthe Netherlands

Personalised recommendations